Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer
Cancer · 2024
DOI: 10.1002/cncr.35222 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer, 2024. Verfasst von David Mutch und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecology Oncology, Washington University School of Medicine, St Louis, Missouri, USA. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Ovarian Neoplasms, Piperidines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: F. Hoffmann-La Roche Ltd..
Abstract (Originalsprache)
Background
This phase 1b study (ClinicalTrials.gov identifier NCT03695380) evaluated regimens combining PARP and MEK inhibition, with or without PD‐L1 inhibition, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer (PSROC).
Methods
Patients with PSROC who had received one or two prior treatment lines were treated with 28‐day cycles of cobimetinib 60 mg daily (days 1–21) plus niraparib 200 mg daily (days 1–28) with or without atezolizumab 840 mg (days 1 and 15). Stage 1 assessed safety before expansion to stage 2, which randomized patients who had BRCA wild‐type PSROC to receive either doublet or triplet therapy, stratified by genome‐wide loss of heterozygosity status (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gynecology Oncology, Washington University School of Medicine, St Louis, Missouri, USA.
- Global Product Development Clinical Science, Roche Products Ltd., Welwyn Garden City, UK.
- Translational Medicine, Genentech, Inc., South San Francisco, California, USA.
- Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Medical Oncology Service, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
- Hospital Clínico Universitario Valencia, Biomedical Research Institute INCLIVA, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Valencia, Spain.
ORCID-Profile: David Mutch, Malgorzata Nowicka
Förderung
- F. Hoffmann-La Roche Ltd.
Zitieren
APA
Mutch, D., Voulgari, A., Chen, X. M., Bradley, W. H., Oaknin, A., Perez Fidalgo, J. A., Montosa, F. G., Herraez, A. C., Holloway, R. W., Powell, M. A., Nowicka, M., Schaefer, G., Merchant, M., & Yan, Y. (2024). Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer. Cancer. https://doi.org/10.1002/cncr.35222
Vancouver
Mutch D, Voulgari A, Chen XM, Bradley WH, Oaknin A, Perez Fidalgo JA, et al. Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer. Cancer. 2024. doi:10.1002/cncr.35222
BibTeX
@article{Mutch2024,
author = {Mutch, David and Voulgari, Athina and Chen, Xian Marissa and Bradley, William H and Oaknin, Ana and Perez Fidalgo, José Alejandro and Montosa, Fernando Galvez and Herraez, Antonio Casado and Holloway, Robert W and Powell, Matthew A and Nowicka, Malgorzata and Schaefer, Gabriele and Merchant, Mark and Yan, Yibing},
title = {Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer},
journal = {Cancer},
year = {2024},
doi = {10.1002/cncr.35222}
}
EUVIMED